Country: Canada
Language: English
Source: Health Canada
ACYCLOVIR
APOTEX INC
D06BB03
ACICLOVIR
5%
OINTMENT
ACYCLOVIR 5%
TOPICAL
4/5/15/30G
Prescription
ANTIVIRALS
Active ingredient group (AIG) number: 0115506007; AHFS:
APPROVED
2018-06-08
_APO-Acyclovir Ointment Product Monograph_ 1 PRODUCT MONOGRAPH PR APO-ACYCLOVIR OINTMENT Acyclovir Ointment 5% w/w, USP ANTIVIRAL AGENT APOTEX INC. 150 Signet Drive Weston, Ontario M9L 1T9 Date of Revision: June 7, 2018 Control Number: 209409 _APO-Acyclovir Ointment Product Monograph_ 2 PRODUCT MONOGRAPH PR APO-ACYCLOVIR OINTMENT Acyclovir Ointment 5% w/w, USP ANTIVIRAL AGENT ACTIONS AND CLINICAL PHARMACOLOGY Apo-Acyclovir Ointment (acyclovir ointment), an acyclic nucleoside analog, is a substrate specific for herpesvirus-specified thymidine kinase. It inhibits replication of these viruses. Normal cellular thymidine kinase does not effectively utilize acyclovir as a substrate. Herpesvirus-specified thymidine kinase transforms acyclovir to its monophosphate which is then transformed by cellular enzymes to acyclovir diphosphate and acyclovir triphosphate. Acyclovir triphosphate is both an inhibitor of, and a substrate for, herpesvirus-specified DNA polymerase. Although the cellular α-DNA polymerase in infected cells may also be inhibited by acyclovir triphosphate, this occurs only at concentrations of acyclovir triphosphate which are higher than those which inhibit the herpesvirus-specified DNA polymerase. Acyclovir is preferentially taken up and selectively converted to its active form by herpesvirus-infected cells. Thus, acyclovir has a very much lower toxic potential for normal uninfected cells because: 1) less is taken up; 2) less is converted to the active form; 3) cellular α-DNA polymerase has a lower affinity for the active form of the drug. INDICATIONS AND CLINICAL USE Apo-Acyclovir Ointment (acyclovir ointment) is indicated for the management of initial episodes of genital herpes simplex infections. It is also indicated in the management of nonlife-threatening cutaneous herpes simplex virus infections in immunocompromised patients. The prophylactic use of this preparation has not been established. In genital herpes, appropriate examinations should be performed to rule out other sexually transmitted disea Read the complete document